Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

Baron, Frédéric; Béguin, Yves

doi:10.1038/bmt.2016.38

Cited by 7 publications

(4 citation statements)

References 23 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients with hematological relapse the dose of CTLs, donor-recipient sex mismatch and chronic GVHD prior to DLI were independently associated with greater probability of reduced OS and secondary GVHD. While they occur at lower levels, GVT effects in the absence of clinical GVHD were also identified in this study, and have been reported elsewhere 44 . Thus GVHD is not a prerequisite for a successful GVT effect, though GVHD often accompanies an effective GVT response.…”

Section: Donor Lymphocyte Infusions (Dli)supporting

confidence: 85%

Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Grant

Bollard

2018

Blood Reviews

View full text Add to dashboard Cite

Cell therapy currently performs an important role in the treatment of patients with various hematological malignancies. The response to the cell therapy is regulated by multiple factors including the patient's immune system status, genetic profile, stage at diagnosis, age, and underlying disease. Cell therapy that does not require genetic manipulation can be mediated by donor lymphocyte infusion strategies, selective depletion in the post-transplant setting and the ex vivo expansion of antigen-specific T cells. For hematologic malignancies, cell therapy is contributing to enhanced clinical responses and overall survival and the immune response to cell therapy is predictive of response in multiple cancer types. In this review we summarize the available T cell therapeutics that do not rely on gene engineering for the treatment of patients with blood cancers.

show abstract

Section: Donor Lymphocyte Infusions (Dli)supporting

confidence: 85%

Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Grant

Bollard

2018

Blood Reviews

View full text Add to dashboard Cite

show abstract

“…Pre-emptive/prophylactic DLI is an acceptable choice especially for those patients who suffer from refractory or relapsed malignancies before transplantation, patients allo-grafted with active uncontrolled disease, patients who received transplantation in CR1 or CR1 >1, AML and ALL patients with high risk for relapse due to the positive minimal residual diseases [ 40 ] and also allo-graft transplanted patients with positive positron emotion tomography (PET) scan suffering from lymphoma. In these circumstances, DLI could be more effective because of the low tumor burden [ 20 ].…”

Section: Pre-emptive/prophylactic Donor Lymphocyte Infusion In Hla Idmentioning

confidence: 99%

Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature

et al. 2017

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor graft function (PGF) after allo-SCT remain to be controversial issues which may affect the transplantation outcome. Relevant articles were searched in MEDLINE database (2000–2016) using keywords and phrases: donor lymphocyte infusions, allogeneic stem cells transplantation, relapsed hematologic malignancies, booster schedules, cell dose, laboratory monitoring protocols and technical aspects of apheresis. Relapse of disease and PGF could be reduced via noting some main points such as choosing the suitable time and patient for donor lymphocyte infusion (DLI) and also determination of patients who ought to candidate for second allogeneic HSCT or for the use of stem cell boost. DLI and stem cell booster are promising treatment strategies noted in this review. Finally, this paper discusses indications and technical aspects of DLI and stem cell booster in hematological malignancies and emphasizes their therapeutic or pre-emptive potentials.

show abstract

“…Unmodified DLI [35][36][37][38][39][40][41][42][43][44] Infusion of donor lymphocytes to mount GVT response Modified DLI [45][46][47][48][49]71 Depletion of DLI subpopulations, T REG , naive T cells, to select for most potent CTLs…”

Section: Treatment Approach Descriptionmentioning

confidence: 99%

Developing T-cell therapies for lymphoma without receptor engineering

Grant

Bollard

2017

Blood Advances

View full text Add to dashboard Cite

T-cell therapy has emerged from the bench for the treatment of patients with lymphoma. Responses to T-cell therapeutics are regulated by multiple factors, including the patient’s immune system status and disease stage. Outside of engineering of chimeric antigen receptors and artificial T-cell receptors, T-cell therapy can be mediated by ex vivo expansion of antigen-specific T cells targeting viral and/or nonviral tumor-associated antigens. These approaches are contributing to enhanced clinical responses and overall survival. In this review, we summarize the available T-cell therapeutics beyond receptor engineering for the treatment of patients with lymphoma.

show abstract

Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

Cited by 7 publications

References 23 publications

Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature

Developing T-cell therapies for lymphoma without receptor engineering

Contact Info

Product

Resources

About